Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hey Grant and BRIG, I know you guys like to quote SA authors when negative AMRN news comes out. There's a new article from The Specialist, a perennial Bear, over there. Thought you'd want to jump on it!
Thanks for your thoughts, hope you enjoy the scam!
Yeah, so, on the ah Tinnitus thing.....I, uh, think I'm gonna stick with the ringing in my ears. Maybe make a pot of coffee and think it over. Honestly, it gets a lot better after a couple of cigarettes and a few Rum and Cokes!! (Lol - I'm just goofing)
Kaku, read more carefully. STS was referring to his use of OmegaJoy +EPA @ 2g/day, prior to starting use of prescription Vascepa. Good luck trading!
Zuman, it doesn't look good for V in this particular instance since in other cancer-related cell death studies, V facilitated Apoptosis. Here they indicate that Apoptosis is a causal factor.
Biobill, I don't know if your predictions could possibly ever see the light of day, but I just love the way you think!!! My hat is off to you sir! This is becoming a blast, gotta love it........
GLTA
Looks like Epadel probably could have an impact on global sales of Vascepa dependent on rules in each country, but I don't think they have rights to sell in US. Patents and lack of FDA approval keep them out.
Isn't it true though that Mochida can't market Epadel in the US because they never pursued approval with the FDA? I would think that "No Epadel = No Generic", right? Also I don't recall reading whether they had ever applied for patents with the USPTO. Wouldn't that mean Vascepa has them trumped no matter what?
Thanks Zu, Yoyo and BioB. The patent portfolio is absolutely dynamite, someone else mentioned that maybe Joe should sub out his Patent Team!
Hey Zu, not exactly sure where I lost my cognitive abilities but I'm confused on this post, is this patent filed for Vascepa or Epanova?
Good day North, I went searching for that post, (10 Reasons to Prescribe Amarin), but haven't found it yet. If you recall the source ID, please post once again. Thanks!
Well BRIG, as an ardent adherent, I understand your need for emphasis in promoting the Short case. But it is dishonest, at best, to represent the article from Raven as attempting to "Rip Amarin BS". He sums up his position as being "cautiously bullish" on Amarin, an assessment that is 180 degrees removed from your assertion.
Vascepa for DM-2 and Crohn's
A little while back, someone posted Trial Results for studies done on Type 2 Diabetics and on Crohn's/IBS patients. Am I recalling this correctly or should I be taking V for my acute cognitive disorder?
Well BaaBaa, there's nothing sheepish about your attitude towards Amarin!! (sorry, couldn't stop myself)
Just a brief comment about side effects for Lovaza vs Vascepa. I was prescribed Lovaza for high trigs and I took it for 6 months. I couldn't handle the side effects any longer so against doctor's orders, I just stopped.
The burping could go on for several hours and it was accompanied by this lovely fishy taste that you could even smell. It may have been this alone that gave me frequent bouts of nausea or perhaps the drug itself. The changes in taste perception were also very significant.
On Vascepa now and occasionally I will sense a little grumbling in my gut after taking dose, but that's been the worst of it. I have digestive problems so perhaps my experiences lean toward the extreme, but Vascepa is easy to take and tolerate. Lovaza for me was really disagreeable.
I won't say I'm excited but my interest has been piqued! I've looked everywhere I could think to look and haven't found anything relevant. There were several AH Pharma acquisition stories. I'm just hoping the AMRN action wasn't just a "sympathy" trade.
Speaking of those AH announcements, I was holding 2000 shs of TSRX last week that I bought around 7. When the price run got rolling, I tried to protect my gain by putting on a GTC Trailing Stop order at 7%. Serendipity I guess! The stock was over 11 and still running so I felt OK about it. I wasn't watching early trading one of those mornings and when I did look, I saw that the bastards had walked it down right past my number and then right back up again. They stole it from me at 10.42!
I can't really bitch about it because I made some money, but it still feels like the guys on the inside cheated me. I mean, they took it down to 10.35 for no apparent reason, just enough to grab my shares, and right back up to over 12. Been trying to buy it back on a dip to 11 but no such luck and it's out of my grasp tonight. It's tough to make any real money as a retailer.
1mill, I'm with you on that.....from your lips to Go......Joe's ears! Hope he provides a little steam at CC but if he doesn't, product will eventually win out (in spite of Him)!
Well God Bless You 1millman! The avatar you selected is PERFECT.....every time I see a picture of dear Ronnie, I can't help thinking of an Insurance Salesman. LOL. I've been absolutely hammered in this AMRN quest but I still believe the science and product are spectacular! I know you are relatively new to this board but it's good to greet a fellow LONG! Best of luck to you and everyone else (long or short) as well!
P.S. Although I have to point out BRIG_88, you're a tough guy to love!
First 30-day script free with coupon from Amarin. "VascepaSavings.com"
With you there on the "snake oil" moderators BiotechWill, but so far haven't discovered any way to eliminate them.
Zumantu and BioBill commented on this new composition patent earlier. Steve Rosenman on SA had a further clarification to add.
SIGNIFICANT AMRN DEVELOPMENT--Price Target Change
Jul 16, 2013 9:55 AM | about stocks: AMRN
Amarin was given notice of allowance for a very important patent - 669 that protects the Anchor population against other Rx. It also would provide legal protection, should Amarin want it against OTC products. This determination comes far earlier than expected and without further back and forth with USPTO. The bottom line is that no formula containing more than 4% DHA can participate in Anchor - meaning no other Rx, including Epanova. Amarin will be the only one to address the market, and the patent goes out beyond the current 2030 date on AMRN's other IP.
Because Anchor approval is around the corner, I am increasing my price target to $35, BD talks and BO should conclude before or shortly after FDA approval of Anchor.
FDA - Incompetence or Fraudulence? It is beyond comprehension that the FDA has failed again to act on the NCE decision for Vascepa. The damage that has befallen our investment in Amarin over the last year is incalculable and much of that lies at the FDA doorstep! Although I acknowledge that it is likely to be futile, it is my fervent wish that BioBill really does have some completely unexpected surprise connection with the Feds. The perpetrators of this fraud at the FDA truly deserve to be dragged through the dirt. They are despicable human beings!
I say "GO FOR IT" and don't cover until capitulation is kaput! That way you squeeze every nickel out of this loser....oh and BTW, you probably shouldn't even bother watching this pig! Tell all your buds what the plan is, everybody should make a killing on this one.
Now if things don't work out exactly according to plan, don't fret about that....just remember it'll be me collecting the premiums when the covering squeeze gets rolling! And I'm your friend....I'll be taking care of you just like you've been taking care of me! Now that's gonna be a party!
BTW, there's certainly a good chance that the intra-day price may not be sustainable, but if it holds up.......it'd be a great way to move into next week's trading news!
The current positive move in AMRN is fairly modest but still warrants a little trumpet blowing. If anyone nibbled on PUTs today, and made a point of publishing that information, one would think they'd have skin thick enough to take a friendly little jab! Guess some folks really do have no sense of humor.....LOL
Which is, in fact, where you obviously belong AK.....because you persist in irritating these learned Cardiologists with tidbits of new knowledge heretofore unknown to them. And how dare you, a pedantic layman......Pshaw!!!
(Just havin' some fun on a quiet night!)
from RAWNOC:
Hearing some really NASTY rumors on AMRN.....
Anybody else hear anything?
Not A Word.....Surprising I Guess?
After reading the posted actual ingredients in Silversword, I'd argue that there isn't anything natural about using this product.....Tibetan Donkey Kidney?.....Yak Testicles?.....Seahorses? Maybe I'll just keep the limp dick.....LOL.
Congratulations are in order, BRIG.....although I resent your low-brow bullshit, it's clear that you've been repeatedly successful with your strategy of shorting AMRN. I believe that opportunity will come to a close soon, but you've done a hell of a lot better than all the die-hard longs (myself included). Going forward, you'll need to stay on your toes! Good luck!
Amen....and amen again to that, brother!!
I also have CVS/Caremark managing my prescription coverage. When I approached them with my 90-day prescription and Vascepa Savings certificate, they checked the pricing. They said it would cost me around $124.00 for 90 days. Then they looked up a 30-day price with the coupon, $0.00 for the first fill, $25.00 for second and subsequent. Guess which I opted for, currently into second month.
The word is efficaCy.
Amarin's Anchor Will Hold As Vascepa's Sails Unfurl
seekingalpha.com/article/1514152-amarin-s-anchor-will-hold-as-vascepa-s-sails-unfurl?source=yahoo
Looks like another month with no decision.........OB Updated!
BioB, I managed to find your post #5913 in which you discussed EPA absorption from Vascepa and from Lovaza and you also included corresponding FDA reference material. Although my memory of the exact processes did not hold up well, I at least retained the major points.
Specifically, Vascepa causes a much higher circulating level of EPA than Lovaza/"fish oil". EPA Cmax for 2gr dose of Vascepa was 155 mcg/ml and for 4gr dose was 347 mcg/ml. EPA Cmax for 8gr dose of Lovaza was 83 mcg/ml.
Now considering PlusEPa, there may not be any study results available that establish EPA Cmax but I see no reason why I can't work out a reasonable estimate by using the Lovaza data. There appears to be a clearly linear ratio for ingested EPA to the subsequent EPA that shows up in serum.
I'll do a little more work on that later this morning and develop some numbers from that ratio based on PlusEPA dosages.
BTW, a big thanks to all the knowledgable posters who've shared their research on this board. It is really appreciated by all of the serious investors here!
Bio -
I am already a 4gr/daily Vascepa user. I had recalled you posting a stat on serum levels for comparable doses of Lovaza and Vascepa. The serum concentration of EPA from Vascepa was much higher than from Lovaza.
I believe you explained that this was likely because the EPA in Lovaza was partially digested in the stomach leaving a lower percentage for absorption into the blood. E-EPA from Vascepa requires metabolic action with Pancreatase for conversion to EPA. This occurs in the intestine so larger percentage available for absorption.
I've seen a few posters touting Plusepa (@90% EPA) over Vascepa. One concern is that there are heavy metals and other toxins at very low concentrations in Plusepa.....I believe any of these contaminants, if present at all in Vascepa, are at even lower concentrations. Slight positive for Vascepa!
Another concern is dosing and to judge advantages there requires knowledge of serum levels of EPA after equivalent dosages. So do 4 grams of Vascepa make more EPA available than 4 grams of Plusepa? Whatever the answer, this is an "apples to apples" comparison if the data can be obtained. Then we can extrapolate consumption requirements to achieve equivalence and thereby accurate costs for each therapy.
Plusepa looks like one of the only possible DS to compete capsule for capsule with Vascepa, in terms of EPA volume. But it's meaningless if the serum levels obtained aren't equivalent as well. That's the information I'm interested in obtaining.
First, Biobill, thanks for all your efforts in posting timely information for the rest of us. I believe I speak for many when I say that! Second, a brief question - have you come across any data that quantifies bioavailability for equivalent doses of Vascepa and Plusepa (90% EPA)? I've already seen your findings on Vascepa. Thanks and good health to you.
Go for it Akanz....I've been on it for the last month at 4 grams and for the prior 45 days at 2 grams. I have serious spinal problems in addition to cardiac issues. There most definitely is an anti-inflammatory effect, maybe not miraculous but it is real and significant. I have blood lipids from period just prior to boosting dose to 4 grams, excited about lab results after 90 days at 4 grams! Do it brother!
Next OB doesn't fall on a monthly Options Expiration for a change. Let's see how the MMs and HFs handle themselves on the 14th.